Releases - AstraZeneca

View:
 

Found press releases

 

ASTRAZENECA APPOINTS MARC DUNOYER AS EXECUTIVE VICE PRESIDENT, GLOBAL PORTFOLIO ...

3/21/2013 8:43 AM EST
AstraZeneca today announced that Marc Dunoyer is to join the company in the newly created role of Executive Vice President, Global Portfolio & Product Strategy.

Marc will be responsible for driving business strategy, including business development, mergers and acquisitions, portfolio and product strategies. His most critical priorities will be to bolster the core growth platforms and therapy areas through well...

ASTRAZENECA OUTLINES STRATEGY TO RETURN TO GROWTH AND ACHIEVE SCIENTIFIC LEADERS...

3/21/2013 3:02 AM EST
21 March 2013

AstraZeneca will today outline its strategy to return to growth and achieve scientific leadership. Results of the annual strategy review will be presented at AstraZeneca’s Investor Day briefing in New York.

Chief Executive Officer, Pascal Soriot said: “AstraZeneca is committed to delivering great medicines to patients through innovative science and excellence in development and commercialisation. Our...

SECOND QUARTER AND HALF YEAR RESULTS 2012

7/26/2012 2:01 AM EST
As expected, generic competition and challenging market conditions reflected in lower second quarter revenues. Progress made on execution of long-term priorities, with the on-market portfolio and the pipeline strengthened through recent business development initiatives. Financial targets for full year unchanged.
Revenue for the second quarter was $6,660 million, down 18 percent at constant exchange rates...

BRISTOL-MYERS SQUIBB AND ASTRAZENECA EXPAND DIABETES ALLIANCE THROUGH BRISTOL-MY...

7/2/2012 2:26 AM EST
Strengthens leadership position of successful alliance in growing area of high unmet
medical need
Complements current portfolio creating a more comprehensive disease management
platform with the addition of novel GLP-1 franchise

Adds approved and marketed products for type 2 diabetes, including BYETTAÒ
and BYDUREONÒ
July 2, 2012

Note to editors: This press release was sent out by AZ global Media team on June...

ASTRAZENECA AND MERCK AGREE TO AMEND SECOND OPTION

6/27/2012 7:09 AM EST
AstraZeneca today announced that AstraZeneca and Merck have agreed to amend certain provisions of the agreements relating to the companies’ arrangements in the United States.

AstraZeneca believes that the amendments provide a greater degree of certainty to the valuation of the Second Option that is preferable to the previous arrangements and, barring unforeseen circumstances, the company now intends to exercise the...

Återköp av aktier - information om utskick

6/1/2012 8:54 AM EST
Vi ser över hur vi kan effektivisera och förenkla vår kommunikation. Denna information finns framöver på bifogad länk. Informationen finns även tillgänglig på astrazeneca.se/aktieägare/aktieinformation. Detta utskick upphör därför per 1/6 2012. Vi frågor, kontakta: Ann-Leena Mikiver, presschef, 08-553 26020. http://www.londonstockexchange.com/exchange/news/market-news/market-news-home.html

REPURCHASE OF SHARES IN ASTRAZENECA PLC

5/31/2012 6:54 AM EST
AstraZeneca PLC announced that on 30 May 2012, it purchased for cancellation 700,000 ordinary shares of AstraZeneca PLC at a price of 2603 pence per share. Upon the cancellation of these shares, the number of shares in issue will be 1,263,508,760. A C N Kemp Company Secretary 31 May 2012

REPURCHASE OF SHARES IN ASTRAZENECA PLC

5/30/2012 7:53 AM EST
AstraZeneca PLC announced that on 29 May 2012, it purchased for cancellation 150,000 ordinary shares of AstraZeneca PLC at a price of 2626 pence per share. Upon the cancellation of these shares, the number of shares in issue will be 1,264,197,399. A C N Kemp Company Secretary 30 May 2012

REPURCHASE OF SHARES IN ASTRAZENECA PLC

5/25/2012 7:54 AM EST
AstraZeneca PLC announced that on 24 May 2012, it purchased for cancellation 153,000 ordinary shares of AstraZeneca PLC at a price of 2605 pence per share. Upon the cancellation of these shares, the number of shares in issue will be 1,264,461,837. A C N Kemp Company Secretary 25 May 2012

REPURCHASE OF SHARES IN ASTRAZENECA PLC

5/24/2012 9:58 AM EST
AstraZeneca PLC announced that on 23 May 2012, it purchased for cancellation 600,000 ordinary shares of AstraZeneca PLC at a price of 2610 pence per share. Upon the cancellation of these shares, the number of shares in issue will be 1,264,610,194. A C N Kemp Company Secretary 24 May 2012

AstraZeneca

RSS

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, ...

View more


  CONTACT  
  • Anna Carbin-Åhlund - Press Contact
  • +468-553 269 39
  •